[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"testosterone\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:testosterone":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,85,111,138,161],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100631445","phase-2-clinical-evaluation-of-subcutaneous-testosterone-implants-in-men-with-symptomatic-hypogonadism-100631445",false,"NCT07500766","Clinical Evaluation of Subcutaneous Testosterone Implants in Men With Symptomatic Hypogonadism","Inclusion Criteria:\n\n* Absence of desire for future fertility.\n* Two fasting total testosterone measurements ≤ 350 ng\u002FdL obtained between 6:00 and 10:00 a.m.\n* A positive ADAM questionnaire result (Participants with a prior diagnosis of testosterone deficiency established at this institution who are currently receiving testosterone replacement therapy and wish to participate in the study will be eligible for inclusion after completion of an appropriate washout period of the testosterone formulation in use.)\n\nExclusion Criteria:\n\n* Inability to complete or respond to study questionnaires.\n* Body mass index (BMI) \\> 35 kg\u002Fm².\n* Untreated depression, defined as a Beck Depression Inventory score \\> 20.\n* Personal history of cancer.\n* Suspicious findings on digital rectal examination or breast examination.\n* Prostate-specific antigen (PSA) \\> 4 ng\u002FmL.\n* History of thrombosis.\n* Known thrombophilia.\n* Erythrocytosis.\n* Polycythemia.\n* Elevated liver enzymes (AST or ALT \\> 1.5 times the upper limit of normal).\n* Untreated chronic disease.\n* Heart failure classified as New York Heart Association (NYHA) class III or IV.\n* History of cardiovascular disease within the previous 6 months.\n* Substance use disorder or alcohol dependence.\n* Use of antiandrogen medications (flutamide, bicalutamide, enzalutamide, apalutamide, spironolactone, cyproterone acetate, abiraterone, ketoconazole, dutasteride, finasteride).\n* Use of estrogenic medications (estradiol, conjugated estrogens, progestogens).\n* Use of anabolic androgenic steroids without medical indication.\n* Untreated hypothyroidism.\n* Known allergy or hypersensitivity to testosterone or any component of the implant (testosterone, stearic acid).","MALE","18 Years",{"count":18,"type":19},30,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","Introduction:\n\nMale hypogonadism is a clinical syndrome associated with significant consequences for health and quality of life. In Brazil, approved testosterone replacement therapy options are limited to injectable formulations and transdermal gels, which are often associated with suboptimal adherence. Subcutaneous testosterone implants, already used in the United States and recommended by international guidelines, represent a promising alternative but are not yet available in Brazil.\n\nObjective:\n\nTo evaluate the efficacy, safety, pharmacokinetics, and quality-of-life impact of 200 mg testosterone implants manufactured in Brazil for the treatment of men with symptomatic hypogonadism.\n\nMethods:\n\nThis is a prospective interventional study conducted at the Division of Urology of the Hospital das Clínicas, University of São Paulo School of Medicine (FMUSP). Thirty cisgender hypogonadal men meeting strict inclusion and exclusion criteria will be enrolled. Participants will receive subcutaneous testosterone implants totaling 800 mg and will be followed for six months. Serial blood sampling will be performed to assess hormonal levels (total and free testosterone, LH, FSH, and PSA) and metabolic parameters (lipid profile, body mass index, and waist circumference). Validated questionnaires, including the IIEF-15, ADAM, and WHOQOL-BREF, will be used to evaluate sexual function, hypogonadal symptoms, quality of life, and patient satisfaction.\n\nOutcomes:\n\nThe primary outcome is the ability of the implants to achieve and maintain therapeutic serum testosterone levels (450-800 ng\u002FdL). Secondary outcomes include pharmacokinetic profile (Cmax, half-life, and mean duration), metabolic effects, changes in quality of life, and treatment adherence.\n\nClinical Significance:\n\nThis study advances the understanding of a testosterone replacement modality that may offer greater convenience for selected patients and for which data on nationally manufactured products are currently lacking. Over a six-month period, the study will investigate laboratory behavior, clinical impact, and patient satisfaction.\n\nRelevance and Impact:\n\nThis is the first study of its kind conducted in Brazil, combining methodological rigor with a robust design to evaluate the safety and efficacy of domestically manufactured testosterone implants. The methodology incorporates detailed ethical and scientific criteria, ensuring high-quality data. The results may support regulatory and clinical decision-making, benefiting patients and potentially contributing to the Brazilian Unified Health System (SUS).",[25,26,27,28],"Male Hypogonadism","Testosterone Deficiency","Testosterone Replacement Therapy","Testosterone",[30,31,32],"testosterone pharmacokinetics","testosterone pharmacodynamics","testosterone pellets","NOT_YET_RECRUITING","2026-03-24",{"date":36,"type":37},"2026-03-30","ACTUAL",{"date":39,"type":19},"2026-03",{"date":41,"type":19},"2027-04",{"name":43,"class":44},"University of Sao Paulo","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":15,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":20,"phases":56,"briefSummary":57,"conditions":58,"keywords":64,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100628386","phase-2-trial-of-statin-therapy-effect-on-androgen-status-and-erectile-function-in-men-100628386","NCT07460960","TRIal of STatin Therapy Effect on Androgen Status and Erectile functioN in Men","A Randomized Controlled Trial of Statin Therapy Effect on Androgen Status and Erectile Function in Men With High and Very High Cardiovascular Risk","Inclusion Criteria:\n\n* male patients aged 40-65 years, sexually active\n* high and very high risk of cardiovascular events (The Systematic Coronary Risk Evaluation 2 (SCORE2))\n* absence of previous statin therapy for 3 months\n* there are no known cardiovascular diseases requiring the appointment of statins in high doses from the start of treatment\n* the invariance of concomitant therapy for 3 months, if the patient needs it.\n\nExclusion Criteria:\n\n* known statin intolerance\n* known hypogonadism\n* persistent forms of atrial fibrillation\n* active malignant neoplasm requiring treatment at the time of screening\n* known chronic inflammatory diseases (rheumatoid arthritis, systemic connective tissue diseases, metabolically associated fatty liver disease, etc.)\n* impaired renal function (estimated glomerular filtration rate \\\u003C30 ml\u002Fmin\u002F1.73 m2) and liver (transaminase levels more than 3 times reference values, bilirubin levels more than 2 times reference values)\n* chronic heart failure\n* a well-known diagnosis of mental illness\n* alcoholism and drug addiction\n* glucocorticoid therapy and regular therapy with nonsteroidal anti-inflammatory drugs (80% of the time for 3 months before switching on)\n* participation in any other clinical trial during this trial, including participation in the trial for 30 days prior to providing informed consent\n* the patient's inability to understand the essence of the study and consent to participate in it","40 Years","65 Years",{"count":55,"type":19},150,[22],"Aim. To study the effect of different intensities of statin therapy on androgen status and erectile function in men aged 40-65 years with high and very high cardiovascular risk. Additionally, to assess the association between sex hormone levels, erectile function parameters, and traditional cardiovascular risk factors, arterial stiffness, and endothelial function in this patient category.\n\nMaterial and methods. It is planned to conduct a prospective randomized controlled trial, including 150 male patients aged 40-65 years, undergoing routine preventive examinations in the clinic of Moscow State University, having a high and very high risk of cardiovascular diseases and meeting the inclusion criteria. Group Pit (n=75) will receive pitavastatin at a starting dose of 1 mg\u002Fday. Group Ros (n=75) will receive rosuvastatin 20 mg\u002Fday. After 3 months, the biochemical parameters will be monitored, and dose titration of pitavastatin to 2-4 mg\u002Fday and\u002For rosuvastatin to 40 mg\u002Fday will be performed if necessary. Patient recruitment to the study will occur over 9 months at a single research center. Patients will be monitored with an objective assessment of erectile function parameters, blood analysis (including androgen status), central arteries stiffness, and endothelial function for 6 months from the moment of activation. Follow-up visits are scheduled at 1, 3 and 6 months.\n\nResults. The expected result of testing the research hypothesis is that statin therapy will not have a negative effect on androgen status and erectile function in men. Intensive statin therapy will have a greater positive effect on endothelial function, which may lead to an improvement in men's erectile function.\n\nConclusion. The study was planned under the assumption that statin therapy would not have a negative effect on androgen status and erectile function in men aged 40-65 years. It is also suggested that the positive effect of statins on endothelial function and vascular stiffness may lead to an improvement in erectile function among men with high and very high cardiovascular risk. If the hypothesis is confirmed, the results obtained will help improve statin treatment adherence in male patients and, as a result, increase the effectiveness of prevention of cardiovascular events.",[59,60,61,62,63,28],"Erectile Dysfunction Due to Arterial Disease","Atheroscleroses","Erectile Disfunction","Endothelial Dysfunction","Androgen Profile",[65,66,67,68,69,70,71,72,73],"cardiovascular diseases","erectile dysfunction","androgen status","atherosclerosis","statins","statin therapy","coronary artery disease","endothelial dysfunction","testosterone","RECRUITING","2026-03-12",{"date":77,"type":37},"2026-03-16",{"date":79,"type":37},"2026-03-05",{"date":81,"type":19},"2027-12",{"name":83,"class":44},"Lomonosov Moscow State University Medical Research and Educational Center",1,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":84},"100598844","serum-testosterone-level-on-angiographic-complexity-of-coronary-lesions-in-premature-ischemic-egyptian-males-100598844","NCT07076771","Serum Testosterone Level on Angiographic Complexity of Coronary Lesions in Premature Ischemic Egyptian Males","Impact of Serum Testosterone Level on Angiographic Complexity of Coronary Lesions in Premature Ischemic Egyptian Males","Inclusion Criteria:\n\n* Male patients aged \\\u003C45 years.\n* Diagnosed with premature ischemic heart disease.\n* Undergoing elective coronary angiography for suspected coronary artery disease (CAD) .\n\nExclusion Criteria:\n\n* History of acute coronary syndrome within the preceding 3 months.\n* Prior diagnosis of hypogonadism or history of testosterone replacement therapy or anabolic steroid use.\n* Active neoplasm or history of chemotherapy.\n* Known hepatic cirrhosis, chronic kidney disease, or end-stage renal disease.\n* Use of medications known to affect sex hormone levels (e.g., spironolactone, ketoconazole).\n* Endocrine disorders such as sickle cell anemia or celiac disease.","45 Years",{"count":94,"type":19},50,"OBSERVATIONAL","This study aims to investigate the association between serum testosterone levels and the angiographic complexity of coronary artery lesions in male patients under 45 years of age presenting with premature ischemic heart disease.",[28,98,99,100,101],"Angiographic Complexity","Coronary Lesion","Premature Ischemia","Males","2025-07-12",{"date":104,"type":37},"2025-07-22",{"date":106,"type":37},"2025-01-01",{"date":108,"type":19},"2025-08-01",{"name":110,"class":44},"Sohag University",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":118,"sex":15,"minAge":119,"maxAge":53,"enrollmentInfo":120,"targetDuration":4,"studyType":20,"phases":122,"briefSummary":124,"conditions":125,"keywords":126,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":84},"100595115","effectiveness-of-qualia-testosterone-supplementation-on-testosterone-levels-100595115","NCT07028255","Effectiveness of Qualia Testosterone Supplementation on Testosterone Levels","Effectiveness of Qualia Testosterone Supplementation on Testosterone Levels: A Randomized Double-Blind Parallel Trial","Inclusion criteria:\n\nProvide voluntary, written, informed consent to participate in the study Agree to provide a valid cell phone number and are willing to receive communications through text Can read and write English Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly Willing to complete questionnaires, records, and diaries associated with the study.\n\nMale participants aged 28-65 A score ≥27 on the Aging Males Symptom Scale Willing and able to visit a local blood draw facility for required blood sample collections Live within 20 miles of a suitable blood draw facility Willing to not consume any supplements containing Testosterone starting about 2 weeks prior to the baseline blood test test continuing through the intervention period.\n\nExclusion criteria:\n\nKnown food intolerances\u002Fallergy to any ingredients in the product Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer Having had a significant cardiovascular event in the past 6 months Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines On immunosuppressive therapy Individuals who were deemed incompatible with the test protocol Adults lacking capacity to consent Have Hypogonadism",true,"28 Years",{"count":121,"type":19},60,[123],"NA","This is a randomized, double-blind, placebo-controlled parallel trial designed to assess the efficacy of Qualia Testosterone, a novel dietary supplement, in adult males aged 28 to 65 experiencing symptoms associated with testosterone deficiency. Approximately 60 participants will be randomized to receive either Qualia Testosterone (2 capsules daily) or a matched placebo for 21 days, with dosing administered each morning. The study's primary outcomes are changes in total testosterone, free testosterone (via dialysis), and dihydrotestosterone levels from baseline to Week 3. Secondary outcomes include changes in Aging Male Symptoms Scale scores-encompassing psychological, somatic, and sexual domains-as well as safety and tolerability. Blood samples will be collected in a laboratory setting, while symptom and safety assessments will be completed electronically at home.",[28],[127,73],"testosterone supplementation","2025-06-11",{"date":130,"type":37},"2025-06-19",{"date":132,"type":19},"2025-07-01",{"date":134,"type":19},"2025-10-01",{"name":136,"class":137},"Qualia Life Sciences","INDUSTRY",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":144,"minAge":16,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":84},"100553566","new-onset-chronic-pelvic-pain-in-transgender-people-using-testosterone-therapy-an-exploratory-qualitative-study-100553566","NCT06487754","New-onset Chronic Pelvic Pain in Transgender People Using Testosterone Therapy: an Exploratory Qualitative Study.","Inclusion Criteria:\n\n* Being a trans masculine individual\n* Taking a gender affirming hormonal therapy (GAHT)\n* living close to Grenoble\n* having pelvic pain that appeared or were modified after taking GAHT\n\nExclusion Criteria:\n\n* Subject under guardianship or subject deprived of liberty Refusal of voice recording","ALL",{"count":146,"type":19},15,"This descriptive qualitative study aim to describe the characteristics of pelvic pain in transgender (trans) individuals using testosterone therapy and the impact on their quality of life. This study also aim to understand the levers and obstacles to consulting a health care professional.",[149,150,28,151],"Transgender Persons","Pelvic Pain","Gender-Affirming Care","2024-12-12",{"date":154,"type":37},"2024-12-17",{"date":156,"type":37},"2024-09-27",{"date":158,"type":19},"2025-12",{"name":160,"class":44},"University Hospital, Grenoble",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":15,"minAge":168,"maxAge":169,"enrollmentInfo":170,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":172,"conditions":173,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":4},"100562694","comparison-of-the-effect-of-testosterone-administered-for-micropenis-hypospadias-surgery-with-bispectral-index-100562694","NCT06606496","Comparison of the Effect of Testosterone Administered for Micropenis Hypospadias Surgery With Bispectral Index","Comparison of the Effect of Testosterone Administered for Micropenis Hypospadias Surgery With Bispectral Index and Other Parameters in General Anesthesia: A Prospective Observational Study","Inclusion Criteria:\n\n* Ages 1-16\n* Patients with ASA I (Normal healthy patients except for surgery)\n* Patients who will undergo surgery for hypospadias repair\n\nExclusion Criteria:\n\n* Morbidly obese patients (body mass index \\> 40kg\u002Fm2)\n* ASA II-III-IV patients (other groups of patients with additional diseases)\n* Volunteers who do not want to participate in the study","1 Year","16 Years",{"count":171,"type":19},22,"The aim of this observational study is to learn the effects of hormone therapy (testosterone) applied in micropenis hypospadias surgery on the depth of anesthesia under general anesthesia. The main question it aims to answer is: The effect of testosterone therapy on the depth of general anesthesia. Based on these, to comment on the depth of anesthesia of patients who have just started using testosterone for sex change. To follow the depth of anesthesia of patients who have undergone hypospadias surgery with BIS monitoring and to record respiratory parameters under general anesthesia.",[174,28,175],"General Anesthesia","BIS","2024-09-18",{"date":178,"type":37},"2024-09-23",{"date":180,"type":19},"2024-09",{"date":182,"type":19},"2024-12",{"name":184,"class":44},"Namik Kemal University"]